Brief: Anthera announces continuation of simplicity study of sollpura following positive DMC review

Anthera Pharmaceuticals

13/12/2016 13:39

Dec 13 (Reuters) - Anthera Pharmaceuticals Inc  ANTH.O  -  
    * Announces continuation of simplicity study of sollpura 
following positive DMC review 
    * DMC was in unanimous agreement "that there are no safety 
concerns and that study can move forward to enrolling part B" 
    * Plans to report topline data including efficacy and safety 
data in Q2 of 2017 
    * Topline data from phase 3 solution clinical study 
evaluating efficacy and safety of capsule formulation of 
sollpura remains on track for the quarter 
 
Source text for Eikon:  ID:nGNXNNMEWa  
Further company coverage:  ANTH.O  
 
 ((Bangalore.newsroom@thomsonreuters.com))